PSA Testing in Primary Care: Is It Time to Change Our Practice

Frederique Denijs

Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

Year in Review: Prostate Cancer - 2024 Insights and Exciting Prospec…

Jason Hafron

WCLC 2024 Insights: Optimal Management of Malignant Pleural Effusion

Insights from 2024 WCLC

P. Lee

Year in Review 2024 - NSCLC Perioperative Therapy

Oncology 2024 Year in Review

B. Halmos

Year in Review - Prostate Cancer

Oncology 2024 Year in Review

K. Tawagi

Year in Review 2024 - Managing Advanced Prostate Cancer

Oncology 2024 Year in Review

R. Dreicer

Role of Surgery in Locally Advanced NSCLC

Memorial Sloan Kettering Cancer Center

K. Gray

Year in Review - Key Clinical Trials in Prostate Cancer

GWU Urology

Neoadjuvant vs. Adjuvant: A New Paradigm for NSCLC

Total Health

D. Carbone

ESMO 2024 Summary: Key Trial Insights on Managing NSCLC With Low PD-…

ecancer

L. Paz-Ares

The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

Adjuvant & Neoadjuvant Therapy in Early NSCLC With Actionable Genomi…

Fox Chase Cancer Center

J. Reuss

Cancer Screening in Primary Care: An Evidence-Based Review of Outpat…

UNC Lineberger Comprehensive Cancer Center

N. Robertson

IO Advances in Metastatic NSCLC Treatment

Fox Chase Cancer Center

H. Borghaei

EGFRm Lung Cancer: Overview & Treatment Sequence

GRACE

J. Rotow

Ideal Treatment Sequence After ADT + ARPI + Docetaxel for mHSPC

Advanced Prostate Cancer Consensus Conference (APCCC)

K. Fizazi

ESMO 2024 Summary: Management of Oligoprogressive Disease - Patients…

2024 ESMO Annual Meeting Insights Hub

R. Van den Begin

Metastatic EGFRm NSCLC: 1L Therapy Options

University of Colorado Cancer Center

T. Patil

Lazertinib in 1L EGFR-Mutant NSCLC: Unique Mechanism and Benefits of…

Mariam Alexander